Anzeige
Mehr »
Login
Montag, 15.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Im Fokus der Anleger: InnoCan Pharma vor entscheidendem Meilenstein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QD64 | ISIN: US50107A1043 | Ticker-Symbol:
NASDAQ
15.04.24
17:22 Uhr
1,150 US-Dollar
+0,020
+1,77 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
KRONOS BIO INC Chart 1 Jahr
5-Tage-Chart
KRONOS BIO INC 5-Tage-Chart

Aktuelle News zur KRONOS BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.03.Kronos Bio reports Q4 results6
21.03.Recap: Kronos Bio Q4 Earnings1
21.03.Kronos Bio Inc reports results for the quarter ended in December - Earnings Summary1
21.03.Kronos Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
21.03.Kronos Bio, Inc.: Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results126Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half...
► Artikel lesen
21.03.Kronos Bio, Inc. - 10-K, Annual Report1
21.03.Kronos Bio, Inc. - 8-K, Current Report-
07.03.Kronos Bio, Inc.: Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway30Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for...
► Artikel lesen
05.03.Kronos Bio, Inc.: Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting1
05.03.Kronos Bio, Inc. - 8-K, Current Report2
27.02.Kronos Bio, Inc.: Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference1
25.01.Kronos Bio streamlines leadership, cuts CMO,CSO and COO roles4
25.01.Kronos Bio, Inc. - 8-K, Current Report2
19.12.23Kronos Bio swivels focus towards multiple myeloma after AML failure2
19.12.23Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study3
19.12.23Kronos Bio, Inc. - 8-K, Current Report-
18.12.23Kronos Bio falls as co will not proceed with mid-stage trial for cancer therapy5
18.12.23Kronos Bio, Inc.: Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate1.456Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2 New development...
► Artikel lesen
04.12.23Kronos Bio, Inc.: Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference3
27.11.23Kronos Bio, Inc.: Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference3
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1